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FDA Policy on Pharmacogenomic Data in Drug
Development
Janet Woodcock*
My presentation will address policy and developing public
policy in the area of pharmacogenomics. To a great extent, this
discussion so far has remained within the drug and device
industrial community, the scientific community, and the FDA. I
appreciate this opportunity to reach a wider audience.How is any new science or new technology integrated into
existing regulatory, legal, and policy frameworks? We ask these
questions in the context of clinical medicine, insurability, and
payment, and we ask them each time a new science or technology
emerges.
This discussion centers on the new science of
phramacogenomics and how it will be integrated into drug
development and clinical medicine. First, it is important to
understand why pharmacogenomics matters and has to be
integrated into drug regulation. The major barrier to having really'
effective drugs is the variability in the way people respond to drugs
and the inability to predict how they are going to respond. These
factors drive the cost of developing drugs and cause many adverse
reactions to them.
There are two kinds of variability that must be considered.
One is variable effectiveness of drugs. Leaving aside antibiotics
and drugs that are actually not directed at people-those are
actually directed at organisms that get into people-often the
measurable effect seen in randomized trials in populations is small.
Therefore, sponsors have to conduct large studies of effectiveness.
Often, erroneous conclusions are drawn that a drug does not work
or that its efficacy is insignificant because the response rate in the
population is small. The response may be variable in fact, and
some people may respond very well-though the collective
response across the entire population studied may appear
unimpressive. Unfortunately, at the present time, it is difficult to
predict which patients will be responders.
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This same is true on the other side-the toxicity side. All of
today's drugs have some associated risks; if you look at a drug
tested against a placebo, you see that every drug has a consistent
pattern of side-effects over and above what the people on placebo
experience. In fact, given enough data, you can identify consistent
patterns of both common and rare side-effects. Now, some of
these side-effects actually are due to the pharmacologic action of
the drug, and there is no easy way to get around that because it is
related to the beneficial effect of the drug. So, for example, certain
drugs that you take for asthma are going to make you jittery. That
is the same physiological effect that is opening up your airways.
But a lot of the side effects are medically termed idiosyncratic.
What idiosyncratic means in this context is: We do not know the
cause, but there was a cause. We just do not know anything about
it, so it is idiosyncratic. The way we approach drug toxicity in
development is to expose many people to the drug and catalogue
what we see versus placebo; it is all very observational. We say:
This is liver toxicity, or this is a kind of organ toxicity, without
understanding the mechanistic cause. So, ultimately, we may
decide that people with preexisting liver disease should not take a
drug because it has liver toxicity while, in fact, those two things
may be completely unrelated.
Pharmacogenomics, is the science of correlating drug
responses to genetic data-meaning the generation of gene or gene
expression data that correlate genes and observed drug responses.
Pharmacogenomics with a focus on gene sequences and data is
pharmacogenetics. 1 There are many different kinds of data about
pharmacogenetics or genomics that correlate with drug responses.
One is simple polymorphisms in genes-for example, single
changes in genes that impact the production of enzymes that
metabolize drugs in your body. In some cases, if a group of people
is given a drug, some will have the normal level of the drug in the
blood, others have no observable presence of the drug in the blood,
while others have a very high level. Of course, polymorphisms are
relevant to dosing. Individuals without detectable blood levels will
not have any drug effectiveness. Those with extremely high levels
from a normal dose often will be dangerously exposed to toxicity.
So, simply by knowing the relevant polymorphisms, one can
predict the drug exposure that people have. Unfortunately, we do
not have easy ways to test for those drug metabolizing genes at the
moment.
1. Pharinaco refers to drug or medicine; genomics refers to genes.
Genetics refers to gene sequences.
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There are also gene expression patterns. If you take a drug,
your genes will start expressing different RNA in response to
getting that drug. We know that, if it is a liver toxic drug, your
liver will start making little toxic RNA response messages. If one
were to look at those liver cells, one could actually say, "Look, that
liver cell is experiencing some stress or toxicity." So we could
predict, sometimes, toxicity based on gene expression. Another
big problem in therapeutics, contributing to the variability of
therapeutic response, is the fact that diseases are lumped together
for treatment purposes.
At this time, medical practice is predicated on observation. For
example, we still collectively categorize lung cancer as we did one
hundred years ago. We still are not sophisticated. We don't know
what the actual molecular cause of that particular cancer is in that
particular person because we don't look for it. Gene expression
patterns are giving us this opportunity, and there are some breast
cancer therapies actually targeted toward whether or not one is
expressing certain genes. We also perhaps could monitor and
guide therapy based on observed gene expression patterns. Again,
we may determine that a patient's liver is looking a little toxic and,
therefore, we ought to back off a particular therapy and monitor for
toxic responses.
So, in summary, this new science of pharmacogenomics holds
the potential to help us better predict effectiveness and avoid
toxicity. Pharmacogenomics is being applied extensively in drug
development right now to pick candidates products to move into
clinical testing. This science has the potential to revolutionize the
process and really help people by individualizing therapy. Patients
do not want to know if a particular drug is the best one for people
with their ailment, they want to know, "Is this the best drug for
me?" Right now, we seldom can answer that question with genetic
precision; drug selection generally is based on the mean responses
of the disease population as measured. Pharmacogenomics could
revolutionize both drug development and treatment. Imagine the
possibilities for narrowing down treatment to populations most
likely to benefit and eliminating populations likely to suffer
adverse events.
The primary policy problem right now is that most of these
genetic tests are not being evaluated in clinical studies, and they
are not being seen by the regulatory agencies. Application in the
official drug development regulatory process is stymied by concern
about how these tests will be used by the marketing application
reviewers. This could present a real lost opportunity for any
person who wants to take medicine in the foreseeable future.
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So, we need to adopt a regulatory approach that will enable the
free exchange of this information. From a public policy
standpoint, the goal is to advance the science and to move it along
as quickly as possible in a responsible manner because it has such
promise to advance therapeutics and to improve human health.
There is a real human need that compels the timely development of
appropriate regulatory policies-policies for banking data,
patenting, and the list goes on. We need appropriate legal and
regulatory policies put in place to allow things to move forward
responsibly. Moreover, we have to integrate our existing-and
this is what is often very challenging-regulatory and legal
framework with this new science. As a new science emerges, the
laws and policies crafted in an earlier time for an earlier type of
information, data, or science often become awkward
entanglements.
What have we done at the FDA? We have been confronted
with this problem for some time, and the field of science we are
talking about today is really taking off. Initially, in 2002, we had a
scientific meeting between regulators and representatives from the
industrial world-the big 1harma companies, the bio companies,
and the device companies. We invited some academics to talk
about the scientific basics, and we exchanged views and tried to
identify what the problems and opportunities were. The FDA went
back and considered these issues. Then, in 2003, we made a
presentation to the FDA Science Board.3 We proposed developing
a pathway for this type of product, a pathway that we would put
out for public comment. In November of 2003, we released this
proposed pathway, which is a draft FDA guidance document, for
public discussion and comment.4  This is the standard
administrative process: We release proposals, open a docket, and
receive comments, and then we finalize the document.
Subsequent to releasing the document, we had a large
meeting-some 500 people attended this meeting from all different
sectors, to discuss the draft proposals and to generate initial
comments.5 Participants included a wide variety of people and
2. Food and Drug Administration (FDA), Guidance for Industry,
Pharmacogenomic Data Submissions 3 (2005), available at http://www.fda.gov/
cber/gdlns/pharmdtasub.pdf.
3. Id.
4. FDA, Draft Guidance for Industry, Pharmacogenomic Data Submissions
(2003), available at http://www.fda.gov/cder/guidance/5900dft.pdf.
5. The Drug Information Association (DIA), FDA, the Pharmacogenomics
Working Group (PWG), PhRMA, and BIO co-sponsored this meeting, which
was held on Nov. 13 and 14, 2003.
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organizations with interests in drug development. The guidance
document comment period has just closed, and we are trying to
start on the final version of the guidance.6 However, I would say,
guidances are always open for comment. If anyone here is moved
to comment, we will be very happy to get your comment. The
document and information about how to contribute to the docket
are posted on the FDA's web site.
7
Now, what did we put in the proposal? Well, the reason there
was reluctance to do pharmacogenomic testing in drug
development is the following: Sponsors who submit
investigational programs to the FDA, which are called
investigational new drug applications (INDs) or new drug
applications (NDAs) or biologics license applications (BLAs), are
required under the law and regulations to provide certain
information to the FDA.8 So, if they generate that information,
they must send it to the FDA. These sponsors expressed concern
that they do not know how this new information fits into this
framework and what the FDA will do with the information. Drug
development is already a long, arduous, expensive and very
uncertain process, and sponsors expressed reluctance to add any
additional uncertainty to the process. That is the bottom line. In
addition, the regulations that the FDA operates under were written
well before the advent of pharmacogenomics, and so their
applicability is unclear. The FDA draft guidance attempts to
explain how the FDA's current thinking on this new type of data
fits into the current regulatory scheme. We have had to trim off a
few edges to fit it into the regulatory scheme, but I think we have
done a reasonable job.
However we deal with pharmacogenomic (PG) data,
submissions must conform with our regulations. Changing
regulations is an arduous, time-consuming, and very uncertain
process. So, we had to write a guidance that would fit this new
kind of data into existing regulations. Much PG data currently
available is not well enough established scientifically to be suitable
for regulatory decision-making. There are a lot of genotype-
phenotype associations out there. There is a lot of hope and
linking, and there are a lot of papers on different links, but the
scientific and medical meaning is not clear. Given the emerging,
6. The draft guidance was subsequently finalized in March 2005, and all
future references will be to the final version.
7. FDA Dockets Management, http://www.fda.gov/ohrms/dockets/default
.htm (last visited Nov. 2, 2005).
8. 21 C.F.R. §§ 312, 314, & 601 (2005).
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explosive, and varied nature of this science, we recognized the
need for threshold definitions. We started out with the definition
that is in the literature for a biological marker (biomarker): "A
characteristic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention." 9 For valid
biomarker, we added: A biomarker that is measured in an
analytical test system with well-established performance
characteristics.' 0 This definition reflects that we at the FDA are
not going to be able to take data from an unstable or poorly
understood analytical system and make regulatory decisions. Once
a test itself has good analytical characteristics, there needs to be an
established framework or body of evidence, clinical or otherwise,
which elucidates the significance of the test results. However, this
definition does not fully describe the situation in drug
development, which is a dynamic situation where information is
evolving and some data may be proprietary. Therefore, we added
additional definitions. A known "valid biomarker," is one that is
known and accepted by the biomedical community.I A "probable
valid biomarker" is one that has been developed to an appropriate
stage by a specific company, but is not widely accepted. 1 This
reflects the evolving nature of the information.
How do these definitions impact applications? Sponsors must
separate the kinds of data they are submitting and filing with their
applications and fit that into categories. For example, they have to
distinguish data that are not yet validated, or are not sufficiently
understood and are not squarely within the scope of the
regulations. The hope is that this will free companies up to do the
exploratory pharmacogenomic work that we would like to see
them undertake and, consequently, derive discovery of
individualized therapies through patient-tailored research. More
importantly, we hope to raise the likelihood that the FDA will see
more information especially pertinent to safety and effectiveness of
drugs.
The FDA has also developed algorithms that require companies
to submit data during the investigational (IND) stage if the test
results will be used in decision-making in an animal or clinical
9. Biomarkers Definitions Working Group, Biomarkers and Surrogate
Endpoints: Preferred Definitions and Conceptual Framework, 69 Clinical
Pharmacology & Therapeutics 89, 91 (2001).
10. FDA, Guidance, supra note 2, at 17.
11. Id.
12. Id.
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trial. 13 The rationale is that such data are an integral part of the
trial. If the sponsor is going to say, "We are only going to enroll
people who have this genetic test result," then the sponsor has to
explain the test and submit the test. We also expressly recognized
that it is up to the sponsor to decide whether to use test results in
an IND to support scientific contentions about a drug. We also
require submission of test results involving a known, valid
biomarker. Where there is agreement in the biomedical
community, the clinical community or the toxicology community,
and this information has known meaning, then it needs to be
submitted to the FDA, just as any other safety or effectiveness data
have to be submitted to the FDA under the regulations.
People are still worried that this guidance does not solve all the
problems, but we think we are at least making progress toward
devising a scheme that will welcome the new science into drug
development in a responsible manner. Our position also reflects
the fact that we would like those inside the FDA to know what is
going on-to learn what is happening in this field as it happens so
that we can craft reasonable policies in conjunction and be ready to
evaluate the data submitted to us. Considerable data generated in
drug development programs are proprietary and kept confidential.
Gaps in information add a dimension of complication to
understanding statistical and analytic problems, with evaluating
these data and making sense of them. To encourage voluntary
submissions, we have established a voluntary submission pathway,
the Voluntary Genomic Data Submission (VGDS) 14 and assembled
an interdisciplinary team to manage it.
The VGDS, often referred to as a research exemption or safe
harbor provision, is a mechanism by which companies submit their
data and tell us about their exploratory pharmacogenomic work
during drug development. Some early adopters have come in and
have been eager to show us what they are doing, and we have the
opportunity to learn with them. Participants are building FDA
knowledge and helping us craft a reasonable regulatory structure
without being dependent upon decision-making about a particular
drug.
A major question is how will the FDA use voluntary data?
There are people who are worried that the FDA will use the data
against a submitting company, while others are worried that we
will respect the voluntary nature of the submission and
confidentiality to the point of not disclosing data that are in our
13. Id. at 5.
14. Id. at 7.
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possession and are really important. The valid biomarker criteria
should, however, limit this area of controversy considerably-at
least for a while. Unfortunately, for a wide variety of reasons,
including the lack of public availability of assays, we are not likely
to see valid biomarkers soon except in the drug metabolism area.
A major reason we have the FDA looking across all these
studies and developing this guidance is that we need to evolve how
the data could and should be handled. When we publish the final
guidance, we anticipate establishing an advisory committee and
using a public process to facilitate discussion.
Submissions of voluntary data are made under an IND or
NDA, which protects confidentiality. One complication is that the
formal structure for what is required under the law and regulations
to be submitted in support of a marketing application is different
from what has to be submitted under an [ND. Requirements for
marketing applications are more stringent because, before exposing
the whole population of the United States to a drug, the FDA
would like to know everything that has been done about that drug.
Accordingly, we came up with an algorithm that calls for complete
reports of PG studies whether the sponsor wants the results to go
into the drug label, or they are part of the database to support
approval. With full marketing applications, we also ask for a
synopsis of all other PG data, for example, out of a non-validated
system, but this could just be a paragraph in the application.
In summary, we hope that the proposed policy steers a path
between aggressive regulation of a new field, which might have a
real chilling effect on the development of that field, and a hands-
off approach to new science that allows that science to develop
without interaction with regulators. And we are trying to go
further, to encourage an element of voluntary sponsor participation
with regulators that is highly beneficial to the agency and the
public. We think we are moving in the right direction, we have
received a considerable number of comments on the draft, and we
will be evaluating those.
We also are anticipating the integration of pharmacogenomic
data into clinical use-meaning the product label and so forth. The
FDA cannot integrate this new scientific knowledge into a product
label unless it has gone through the clinical trials process and
application process and that is the next regulatory challenge.
The first way we anticipate appearance of pharmacogenomic
information is what we refer to as informational inclusion in the
label. What do I mean by that? Currently, there is a lot of
information on drug metabolism in labels. This drug metabolism
information comes mainly from the phenotype of the patient. A
person who does not metabolize a drug well will have higher blood
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levels than most people. The label for that drug would include
information on what enzymes are responsible for this, but that
would be strictly from the phenotype. Now, you can do this from
the genotype. In other words, you can test a person's genes to
determine how that individual metabolizes the drug. The person
might be told, "Anytime you get a drug that is metabolized by this
pathway, the levels of that drug in your system are going to be too
high because you are a poor metabolizer of any drug that is
metabolized by this pathway." So they could get a profile, a
prediction, that says how they will metabolize drugs.
This type of information will start to get incorporated in drug
labels as genetic tests become available. The label provides advice
to the clinician. It does not direct the clinician to do one thing or
another; it is advisory. When that information starts to be included
in the label, we would like to see the related data in the drug
application just as we presently see phenotypic data.
So, conceptually, how to handle this new data is not that
complicated. The main problem is that patient-specific data often
are not crossing over into clinical practice. There are instances
when everybody receives the same dose of a drug even though, for
decades, there has been a means to predict that certain people are
not going to respond to the drug or are going to respond poorly-
for example, from a particular painkiller because their system does
not turn it into an active drug. They still get that ineffective
painkiller, which is a shame.
Pharmacogenomic data in labels will eventually extend to
directed therapy, meaning instructions to run a genetic test prior to
or during therapy. As this era arrives, we would like to see co-
development of the pharmacogenomic test and the drug together so
they both reach the finish line at the same time-meaning
simultaneous approval of the drug and diagnostic. Clinicians
should be able to order the diagnostic test with confidence in its
reliability in conjunction with the opportunity to write a
prescription for the drug. The centers that regulate drugs and
medical devices 15 are working together to issue guidance on how a
sponsor might develop both products simultaneously. This is a
challenging undertaking, for there are a tremendous number of
validation questions. Nevertheless, we are going to try to issue a
guidance, which means that we will follow the public process and
have a public discussion about what might be required.
15. Center for Drug Evaluation and Research (CDER) and Center for
Devices and Radiological Health (CDRH), respectively.
LOUISIANA LA W REVIEW
Another question, one that is always raised by the firms, is,
"What will the FDA do if specific populations are discovered
during clinical development?" For example, imagine a drug
sponsor that anticipates its drug will be used to treat everyone in
the country with hypertension. What happens if the data show that
there is a smaller group that has a much greater benefit from the
drug, and another at a higher risk from the drug, and so forth? The
sponsors' concern is that the FDA will limit the indication to the
most responsive groups. And this is where the ethicists, venture
capitalists, and everybody else start talking. First of all, recognize
that we absolutely support the development of pharmacogenomic-
directed therapy. Why? Because this is the future of drugs and
therapeutics in the United States if we are going to move beyond
empirical drug development.
Second, we have to recognize that this is an area in transition.
It is a little premature to worry about the FDA limiting populations
when there is no critical mass of pharmacogenomic tests to use in
drug development. Frankly, understanding the utility and the
limitations of pharmagenomics directed therapies will take some
time. Nevertheless, this is a period of change, which is
uncomfortable for many people. It is important to remain focused
on the ultimate goal.
Third, we must remain cognizant of the fact that the traditional
drug development pathway is familiar, established, and has
revolutionized the treatment of many diseases in the United States.
Patients are currently enrolled in trials based on biomarkers
developed by clinical observation and through the application of
traditional scientific methodologies. The traditional pathway may
deliver clinical benefits for some time to come, and it is also a
solid point of reference for dealing with new science. From the
FDA's point of view, whatever patient characteristic is studied, the
overall process ultimately is a hypothesis testing exercise.
Fourth, we must acknowledge that there is a tremendous
amount of hype involved. The reality is that it takes time and
effort to verify the validity of any observed association. At the
FDA, we feel this in our bones because we have experienced this
process so many times-not yet in pharmacogenomics, but pretty
much in all other areas of established medical science.
An occurrence in one trial may not prove to be a repeatable
association, and any association may be confounded by a bouquet
of variables that lead you down a lot of garden paths. An
association that is very statistically significant may arise in a trial
but, the next time that or a similar trial is done, the association is
not visible at all. So any initial finding in a subset of people, no
matter how exciting, must be approached as a hypothesis-
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generating event that must be confirmed. Are there any
exceptions? Perhaps.
My personal theory is that cancer treatments must be
approached more like the development of antibiotics or anti-virals.
Why? The genome you are testing really is not the person's
genome; it is a mutated genome. You are looking at a gene
sequence or expression data in the tumor and trying to
individualize, but not to the person as much as to that person's
individual tumor. This theory is linked to specific hypotheses
about molecular mechanisms of intervention, based on the
molecular mechanism of oncogenesis. Presently, when we look at
tumors, we are highly observational-meaning we characterize
them as lung cancer, liver cancer, and so forth. We may see a shift
from this to treating mutated cells based upon their specific
patterns of mutation.
So, cancer treatments may prove especially conducive to
pharmacogenomic-directed therapies because we are treating
mutated entities within the body. The concept is going to be
applicable in other diseases eventually, but in not as much of a
clear-cut manner. Most diseases are not as mutation-based.
How will the advent of pharmacogenomics impact medicinal
use of approved drugs? The use of many drugs currently on the
market could be tremendously improved by genomically directed
therapy. Nevertheless, our experience so far at the FDA is that we
are going to encounter considerable push-back from the clinical
community on making this transition. The tests are unfamiliar and
costly, and the cost-benefit will be hard to elucidate in many cases.
To illustrate my point, consider testing for TPMT, an enzyme that
metabolizes 6MP, a drug used in childhood cancer therapy, among
other indications. This is a not-so-rare mutation that impedes
metabolizing 6MP, and those individuals get extremely high
exposure to the drug if they are given an ordinary dose.
Accordingly, there has been a push to routinely screen people for
this mutation before they are given 6MP. We formed a public
advisory committee on this topic, and the clinical community is
really quite conflicted. They have a long history of success in
treating childhood leukemia, and they are worried about the
consequences of switching to a genetically tailored dose regimen.
In contrast, if you can screen to eliminate people who are at high
risk for some horrendous side-effect, I believe that is much more
likely to be widely accepted.
Our observation at the FDA at this time is that, outside of
oncology, pharmacogenomic-targeted therapy will consist of using
genetic knowledge to enrich, rather than to cleanly predict,
responses to pharmaceuticals. Most responses are probably going
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to be multi-gene driven, and so reliable prediction will not be
readily possible. It is unlikely that you will have very reliable
prediction of responses in very small groups of people-a common
belief in the basic science community right now. Consider
depression, an extremely variable disease presently treatable with a
collection of antidepressants recognized as effective through
clinical use. If these drugs are tested against a placebo, they fail to
show effect almost fifty percent of the time. 16 The reality is that
we really do not know what depression is. The diagnosis is based
on observation, and it likely is a common symptom for a wide
variety of problems involving variations in brain chemistry.
Pharmacogenomics will introduce deeper understanding, but most
likely with high clinical complexity.
16. Arif Khan et al., Are Placebo Controls Necessary to Test New
Antidepressants and Anxiolytics?, 5 Int'l J. Neuropsychopharmacology 193,
195-96 (2002).
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